TGF beta receptor

Multi tool use
transforming growth factor beta, receptor type I (activin A receptor type II-like kinase, 53kDa) |
Identifiers |
Symbol |
TGFBR1 |
Alt. symbols |
ALK5 |
Entrez |
7046 |
HUGO |
11772 |
OMIM |
190181 |
RefSeq |
NM_004612 |
UniProt |
P36897 |
Other data |
Locus |
Chr. 9 q22
|
transforming growth factor beta, receptor type II (70/80kDa) |
Identifiers |
Symbol |
TGFBR2 |
Alt. symbols |
MFS2 |
Entrez |
7048 |
HUGO |
11773 |
OMIM |
190182 |
RefSeq |
NM_001024847 |
UniProt |
P37173 |
Other data |
Locus |
Chr. 3 p22
|
transforming growth factor beta, receptor type III |
Identifiers |
Symbol |
TGFBR3 |
Alt. symbols |
β-Glycan |
Entrez |
7049 |
HUGO |
11774 |
OMIM |
600742 |
RefSeq |
NM_003243 |
UniProt |
Q03167 |
Other data |
Locus |
Chr. 1 p33-p32
|
Transforming growth factor beta (TGFβ) receptors are single pass serine/threonine kinase receptors that belong to TGFβ receptor family. They exist in several different isoforms that can be homo- or heterodimeric.[1] The number of characterized ligands in the TGFβ superfamily far exceeds the number of known receptors, suggesting the promiscuity that exists between the ligand and receptor interactions.
TGFβ is a growth factor and cytokine involved in paracrine signalling and can be found in many different tissue types, including brain, heart, kidney, liver, bone, and testes. Over-expression of TGFβ can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease. Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis.
Three TGFβ superfamily receptors specific for TGFβ, the TGFβ receptors, can be distinguished by their structural and functional properties. TGFβR1 (ALK5) and TGFβR2 have similar ligand-binding affinities and can be distinguished from each other only by peptide mapping. Both TGFβR1 and TGFβR2 have a high affinity for TGFβ1 and low affinity for TGFβ2. TGFβR3 (β-glycan) has a high affinity for both homodimeric TGFβ1 and TGFβ2 and in addition the heterodimer TGF-β1.2.[2] The TGFβ receptors also bind TGFβ3.
See also
- TGFβ superfamily receptor
- TGFβ signaling pathway
- TGFβ superfamily
References
^ Doré JJ, Edens M, Garamszegi N, Leof EB (November 1998). "Heteromeric and homomeric transforming growth factor-beta receptors show distinct signaling and endocytic responses in epithelial cells". The Journal of Biological Chemistry. 273 (48): 31770–7. doi:10.1074/jbc.273.48.31770. PMID 9822641..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em} (free full text)
^ Cheifetz S, Andres JL, Massagué J (November 1988). "The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor". The Journal of Biological Chemistry. 263 (32): 16984–91. PMID 2903157.
External links
TGF-beta+Receptors at the US National Library of Medicine Medical Subject Headings (MeSH)
Cell signaling: TGFβ signaling pathway
|
TGF beta superfamily of ligands |
TGF beta family |
|
Bone morphogenetic proteins |
- BMP2
- BMP3
- BMP4
- BMP5
- BMP6
- BMP7
- BMP8a
- BMP8b
- BMP10
- BMP15
|
Growth differentiation factors |
- GDF1
- GDF2
- GDF3
- GDF5
- GDF6
- GDF7
- Myostatin/GDF8
- GDF9
- GDF10
- GDF11
- GDF15
|
Other |
- Activin and inhibin
- Anti-müllerian hormone
- Nodal
|
|
TGF beta receptors (Activin, BMP) |
TGFBR1: |
Activin type 1 receptors
- ACVRL1
BMPR1
|
TGFBR2: |
Activin type 2 receptors
- AMHR2
- BMPR2
|
TGFBR3: |
|
|
Transducers/SMAD
|
R-SMAD (SMAD1
- SMAD2
- SMAD3
- SMAD5
SMAD9)
I-SMAD (SMAD6
SMAD7)
- SMAD4
|
Ligand inhibitors |
- Cerberus
- Chordin
- Decorin
- Follistatin
- Gremlin
- Lefty
- LTBP1
- Noggin
- PARN
- THBS1
|
Coreceptors |
|
Other |
|
Receptors: growth factor receptors
|
Type I cytokine receptor |
Nerve growth factors: Ciliary neurotrophic factor
- Erythropoietin
|
Receptor protein serine/threonine kinase |
TGF pathway: TGF-beta
Activin
Bone morphogenetic protein
|
Receptor tyrosine kinase |
|
Nerve growth factors: high affinity Trk
|
|
Somatomedin
- Insulin-like growth factor 1
|
ErbB/Epidermal growth factor
|
|
|
Tumor necrosis factor receptor |
Nerve growth factors: Low affinity/p75
|
Ig superfamily |
Platelet-derived growth factor
- Stem cell factor
|
Other/ungrouped |
Somatomedin
- Insulin-like growth factor 2
|
Cytokine receptors
|
Chemokine receptor (GPCRs) |
CC |
CCR1 / CCRL1
- CCR2
- CCRL2
- CCR3
- CCR4
- CCR5
- CCR6
- CCR7
- CCR8
- CCR9
- CCR10
|
CXC |
IL-8
- CXCR3
- CXCR4
- CXCR5
- CXCR6
- CXCR7
|
Other |
|
|
TNF receptor |
1-10 |
TNFR1 (TNFRSF1A)
TNFR2 (TNFRSF1B)
LTBR (TNFRSF3)
CD134 (TNFRSF4)
CD40 (TNFRSF5)
Fas receptor (TNFRSF6)
DcR3 (TNFRSF6B)
CD27 (TNFRSF7)
CD30 (TNFRSF8)
CD137 (TNFRSF9)
|
11-20 |
DR4 (TNFRSF10A)
DR5 (TNFRSF10B)
DcR1 (TNFRSF10C)
DcR2 (TNFRSF10D)
RANK (TNFRSF11A)
Osteoprotegerin (TNFRSF11B)
TweakR (TNFRSF12A)
TACI (TNFRSF13B)
BAFFR (TNFRSF13C)
HVEM (TNFRSF14)
NGFR (TNFRSF16)
BCMA (TNFRSF17)
GITR (TNFRSF18)
TAJ/TROY (TNFRSF19)
|
21-27 |
DR6 (TNFRSF21)
DR3 (TNFRSF25)
EDA2R (TNFRSF27)
|
|
JAK-STAT |
Type I |
γ-chain |
Interleukin receptors
IL2R / IL2RA/IL2RB / IL15R
IL4R / IL13R / IL13RA1 / IL13RA2
IL7R / IL7RA
- IL9R
- IL21R
|
β-chain |
Interleukin receptors
IL3R / IL3RA
IL5R / IL5RA
- GM-CSF
|
gp130 |
Interleukin receptors
- IL6RA
11/IL11RA
27/IL27RA
- OSMR
- LIFR
- CNTFR
|
IL12RB1 |
Interleukin receptors
IL12R/IL12RB1/IL12RB2
- IL23R23
|
Other |
hormone receptor: GH
- prolactin
|
|
Type II |
Interleukin receptors
IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
IL20R / IL20RA / IL20RB
- IL28R
Interferon receptors
-α/β / IFNAR1/IFNAR2
-γ/IFNGR1 / IFNGR2
|
|
Ig superfamily |
- CSF1
- KIT
IL1
IL18R / IL18R1
|
IL 17 family |
IL17
- IL17RA
- IL17RB
- IL17RC
- IL17RD
- IL17RE
|
S/T |
|
Kinases: Serine/threonine-specific protein kinases (EC 2.7.11-12)
|
Serine/threonine-specific protein kinases (EC 2.7.11.1-EC 2.7.11.20)
|
|
|
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
|
Polo kinase (EC 2.7.11.21) |
|
Cyclin-dependent kinase (EC 2.7.11.22) |
- CDK1
- CDK2
- CDKL2
- CDK3
- CDK4
- CDK5
- CDKL5
- CDK6
- CDK7
- CDK8
- CDK9
- CDK10
- CDK12
- CDC2L5
- PCTK1
- PCTK2
- PCTK3
- PFTK1
- CDC2L1
|
(RNA-polymerase)-subunit kinase (EC 2.7.11.23) |
- RPS6KA5
- RPS6KA4
- P70S6 kinase
- P70-S6 Kinase 1
- RPS6KB2
- RPS6KA2
- RPS6KA3
- RPS6KA1
- RPS6KC1
|
Mitogen-activated protein kinase (EC 2.7.11.24) |
Extracellular signal-regulated
- MAPK1
- MAPK3
- MAPK4
- MAPK6
- MAPK7
- MAPK12
- MAPK15
C-Jun N-terminal
P38 mitogen-activated protein
|
MAP3K (EC 2.7.11.25) |
MAP kinase kinase kinases
- MAP3K1
- MAP3K2
- MAP3K3
- MAP3K4
- MAP3K5
- MAP3K6
- MAP3K7
- MAP3K8
RAFs
MLKs
- MAP3K12
- MAP3K13
- MAP3K9
- MAP3K10
- MAP3K11
- MAP3K7
- ZAK
- CDC7
- MAP3K14
|
Tau-protein kinase (EC 2.7.11.26) |
|
(acetyl-CoA carboxylase) kinase (EC 2.7.11.27) |
|
Tropomyosin kinase (EC 2.7.11.28) |
|
Low-density-lipoprotein receptor kinase (EC 2.7.11.29) |
|
Receptor protein serine/threonine kinase (EC 2.7.11.30) |
Bone morphogenetic protein receptors
- BMPR1
- BMPR1A
- BMPR1B
- BMPR2
- ACVR1
- ACVR1B
- ACVR1C
- ACVR2A
- ACVR2B
- ACVRL1
- Anti-Müllerian hormone receptor
|
|
|
Dual-specificity kinases (EC 2.7.12)
|
MAP2K |
- MAP2K1
- MAP2K2
- MAP2K3
- MAP2K4
- MAP2K5
- MAP2K6
- MAP2K7
|
|
|
TGFβ receptor superfamily modulators
|
Type I |
ALK1 (ACVRL1) |
Agonists: Activin (A, B, AB)
- Avotermin
BMP (10)
- Cetermin
GDF (2 (BMP9))
TGFβ (1, 2, 3)
Antibodies: Ascrinvacumab
Kinase inhibitors: K-02288
- ML-347 (LDN-193719, VU0469381)
Decoy receptors: Dalantercept
Other inhibitors: Disitertide
|
ALK2 (ACVR1A) |
Agonists: Activin (A, B, AB)
- AMH (MIS)
- Avotermin
BMP (5, 6, 7, 8A, 8B)
- Eptotermin alfa
TGFβ (1, 2, 3)
Kinase inhibitors: DMH-1
- DMH-2
- Dorsomorphin (BML-275)
- K-02288
- ML-347 (LDN-193719, VU0469381)
|
ALK3 (BMPR1A) |
Agonists: AMH (MIS)
BMP (2, 4, 5, 6, 7, 8A, 8B)
- Dibotermin alfa
- Eptotermin alfa
Kinase inhibitors: DMH-2
- Dorsomorphin (BML-275)
- K-02288
|
ALK4 (ACVR1B) |
Agonists: Activin (A, B, AB)
GDF (1, 3, 11 (BMP11))
- Myostatin (GDF8)
- Nodal
Antagonists: Inhibin (A, B)
Lefty (1, 2)
Kinase inhibitors: A 83-01
- SB-431542
- SB-505124
|
ALK5 (TGFβR1) |
Agonists: Avotermin
GDF (10 (BMP3B), 11 (BMP11))
TGFβ (1, 2, 3)
Antibodies: Fresolimumab
- Lerdelimumab
- Metelimumab
Kinase inhibitors: A 83-01
- D-4476
- GW-788388
- LY-364947
- LY-2109761
- Galunisertib (LY-2157299)
- R-268712
- RepSox (E-616452, SJN-2511)
- SB-431542
- SB-505124
- SB-525334
- SD-208
|
ALK6 (BMPR1B) |
Agonists: BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
GDF (5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 15)
- Radotermin
Kinase inhibitors: DMH-2
- Dorsomorphin (BML-275)
- K-02288
|
ALK7 (ACVR1C) |
Agonists: GDF (1, 3, 11 (BMP11))
- Nodal
Antagonists: Lefty (1, 2)
Kinase inhibitors: A 83-01
- SB-431542
- SB-505124
|
|
Type II |
TGFβR2 |
Agonists: Avotermin
GDF (10 (BMP3B))
TGFβ (1, 2, 3)
Antibodies: Fresolimumab
- Lerdelimumab
- Metelimumab
Kinase inhibitors: DMH-2
- LY-364947
|
BMPR2 |
Agonists: BMP (2, 4, 6, 7, 10)
- Dibotermin alfa
- Eptotermin alfa
GDF (2 (BMP9), 5 (BMP14), 6 (BMP13), 7 (BMP12))
- Radotermin
Antagonists: Inhibin (A, B)
|
ACVR2A (ACVR2) |
Agonists: Activin (A, B, AB)
BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 11 (BMP11), 15)
- Myostatin (GDF8)
- Nodal
- Radotermin
Antagonists: Inhibin (A, B)
Lefty (1, 2)
Decoy receptors: Sotatercept
|
ACVR2B |
Agonists: Activin (A, B, AB)
BMP (2, 4, 6, 7)
- Dibotermin alfa
- Eptotermin alfa
GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12))
- Myostatin (GDF8)
- Nodal
- Osteogenin (BMP3, BMP3A)
- Radotermin
Antagonists: Inhibin (A, B)
Lefty (1, 2)
Decoy receptors: Ramatercept
|
AMHR2 (AMHR) |
|
|
Type III |
TGFβR3 (β-glycan) |
Ligands: Avotermin
Inhibin (A, B)
TGFβ (1, 2, 3)
|
|
Unsorted |
Endogenous antagonists/inhibitors: BAMBI
- Cerberus (CER1)
- Chordin
- DAN (PARN)
- Decorin
- Follistatin
- Gremlin (Drm)
- LTBP1
- Noggin
- TGIF
- Thrombospondin 1 (THBS1)
- Tomoregulin 1
Antibodies: Stamulumab (against myostatin)
TRC105 (against endoglin)
|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
- Cytokine receptor modulators
|
5zSFSZFGsryw,9hQfv5 ojNvJ Ime2hBESR,i3I1E3wgju7CTNbhC0WWqz
Popular posts from this blog
Florida Star v. B. J. F. From Wikipedia, the free encyclopedia Jump to navigation Jump to search United States Supreme Court case Florida Star v. B. J. F. Supreme Court of the United States Argued March 21, 1989 Decided June 21, 1989 Full case name The Florida Star v. B. J. F. Citations 491 U.S. 524 ( more ) 109 S. Ct. 2603; 105 L. Ed. 2d 443; 1989 U.S. LEXIS 3120; 57 U.S.L.W. 4816; 16 Media L. Rep. 1801 Prior history The Florida Star v. B.J.F., 530 So.2d 286 (1988) Supreme Court of Florida; Florida Star v. B.J.F., 499 So.2d 883 (1986) Fla. Dist. Court of Appeals Holding Florida Stat. § 794.03 is unconstitutional to the extent it makes the truthful reporting of information that was a matter of public record unlawful, as it violates the First Amendment. Court membership Chief Justice William Rehnquist Associate Justices William J. Brennan Jr. · Byron White Thurgood Marshall · Harry Blac...
Danny Elfman From Wikipedia, the free encyclopedia Jump to navigation Jump to search Danny Elfman Elfman at the 2010 San Diego Comic-Con Born Daniel Robert Elfman ( 1953-05-29 ) May 29, 1953 (age 65) Los Angeles, California, U.S. Spouse(s) Bridget Fonda ( m. 2003) Children 1 Musical career Genres Rock [1] ska [2] new wave film music video game music Occupation(s) Composer, singer, songwriter, record producer Instruments Trombone guitar percussion vocals keyboards [3] Years active 1972–present Associated acts Oingo Boingo James Newton Howard Daniel Robert Elfman (born May 29, 1953) is an American composer, singer, songwriter, and record producer. Elfman first became known for being the lead singer and songwriter for the band Oingo Boingo from 1974 to 1995. He is well known for scoring films and television shows, particularly his frequent collabora...
The Sandy Post From Wikipedia, the free encyclopedia Jump to navigation Jump to search The Sandy Post Type Weekly Newspaper Format Tabloid Owner(s) Community Newspapers/Pamplin Media Group Publisher J. Mark Garber Editor Steve Brown Founded 1937 ( 1937 ) Headquarters Sandy, Oregon Circulation 3,800 Website www.pamplinmedia.com/sandy-post-home/ This article needs additional citations for verification . Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (February 2010) (Learn how and when to remove this template message) The Sandy Post is a weekly newspaper, published in Sandy, Oregon, United States. The paper, founded in 1937, serves the communities of Sandy, Boring, the Villages at Mount Hood and the surrounding areas. The newspaper is owned by Community Newspapers/Pamplin Media Group, a company of ...